10:00 AM EST - GT Biopharma Inc : Today announced that the first patient was dosed in a Phase 1 dose escalation basket trial evaluating GTB-5550, its B7-H3-targeted natural killer cell engager for solid tumors expressing B7-H3. The Phase 1 trial with GTB-5550 will be the first nanobody TriKE® tested with more patient-friendly subcutaneous dosing. GT Biopharma Inc
shares N.GTBP are trading up $0.07 at $0.38.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=GTBP&qmodStoryID=7072240946322842
